{"disease":{"id":"gm1-gangliosidosis","name":"gm1 gangliosidosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT04470713","title":"Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2","phase":"","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Idorsia Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT07054515","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Azafaros A.G.","has_results":false},{"nct_id":"NCT04624789","title":"Registry Gangliosidoses","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt)","has_results":false},{"nct_id":"NCT04041102","title":"Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT05109793","title":"GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)","phase":"","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Azafaros A.G.","has_results":false},{"nct_id":"NCT04320329","title":"Natural History of Morquio B and Late-Onset of GM1 Gangliosidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT04310163","title":"Interviews and Video Capture in Patients With GM1 Gangliosidosis","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"LYSOGENE","has_results":false},{"nct_id":"NCT07479953","title":"Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":5,"lead_sponsor_name":"Tippi Mackenzie","has_results":false},{"nct_id":"NCT04273269","title":"A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"LYSOGENE","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}